Inventor · disambiguated record
Christopher D. Benjamin
Also filed as: BENJAMIN CHRISTOPHER · BENJAMIN CHRISTOPHER D
17 granted patents·8 pending applications·582 citations·filing 1989–2020
96Inventor score
Files withBIOGEN INC8BIOGEN IDEC INC7PURDUE RESEARCH FOUNDATION2TAYLOR FREDERICK R2BIOGEN INC A MASSACHUSETTS COR1
Top patents by PatentIndex Score
25 records- 0197US7001598B2Anti-lymphotoxin-beta receptor antibodies as anti-tumor agentsBIOGEN IDEC INC·Filed 2001·Granted Feb 21, 2006·67 cites·132 claims
- 0294US7459537B2Anti-lymphotoxin-β receptor antibodies as anti-tumor agentsBIOGEN IDEC INC·Filed 2005·Granted Dec 2, 2008·11 cites·23 claims
- 0394US5272263ADNA sequences encoding vascular cell adhesion molecules (VCAMS)BIOGEN INC·Filed 1989·Granted Dec 21, 1993·72 cites·9 claims
- 0493US5925351ASoluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseaseBIOGEN INC·Filed 1995·Granted Jul 20, 1999·78 cites·16 claims
- 0590US6312691B1Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agentsFiled 1996·Granted Nov 6, 2001·52 cites·5 claims
- 0689US6770745B2Common gamma chain blocking agentsBIOGEN IDEC INC·Filed 2001·Granted Aug 3, 2004·24 cites·1 claims
- 0788US6403087B1Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of immunological diseaseBIOGEN INC·Filed 1996·Granted Jun 11, 2002·52 cites·14 claims
- 0888US5367056AEndothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)BIOGEN INC·Filed 1993·Granted Nov 22, 1994·50 cites·6 claims
- 0986US6669941B1Soluble lymphotoxin-β receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune diseaseBIOGEN INC·Filed 1999·Granted Dec 30, 2003·42 cites·14 claims
- 1086US6252043B1Vascular cell adhesion molecule (VCAM) polypeptidesBIOGEN INC·Filed 1994·Granted Jun 26, 2001·47 cites·5 claims
- 1182US6307025B1VCAM fusion proteins and DNA coding thereforBIOGEN INC·Filed 1995·Granted Oct 23, 2001·35 cites·7 claims
- 1281US7427403B2Methods for inhibiting lymphotoxin β receptor signallingBIOGEN IDEC INC·Filed 2002·Granted Sep 23, 2008·9 cites·74 claims
- 1380US7951371B2Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signalingBIOGEN IDEC INC·Filed 2007·Granted May 31, 2011·2 cites·12 claims
- 1477US10989681B2Grid coatings for capture of proteins and other compoundsPURDUE RESEARCH FOUNDATION·Filed 2016·Granted Apr 27, 2021·2 cites·17 claims
- 1577US6323027B1Common gamma chain monoclonal antibody blocking agentsBIOGEN INC·Filed 1998·Granted Nov 27, 2001·39 cites·19 claims
- 1668US11965851B2Grid coatings for capture of proteins and other compoundsPURDUE RESEARCH FOUNDATION·Filed 2020·Granted Apr 23, 2024·0 cites·8 claims
- 1768US2009123421A1Anti-lymphotoxin-beta receptor antibodies as anti-tumor agentsBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 1858US8455445B2Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disordersBROWNING JEFFREY L·Filed 2011·Granted Jun 4, 2013·0 cites·16 claims
- 1958US2007149769A1Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)BIOGEN INC A MASSACHUSETTS COR·Filed 2006·Application pending·0 cites
- 2058US2008124278A1Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereofTAYLOR FREDERICK R·Filed 2007·Application pending·0 cites
- 2158US2015017155A1Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereofBIOGEN IDEC INC·Filed 2014·Application pending·0 cites
- 2254US2003153731A1Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)Filed 2002·Application pending·0 cites
- 2353US2006193856A1Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereofTAYLOR FREDERICK R·Filed 2005·Application pending·0 cites
- 2451US2006172346A1Methods of designing and producing novel compounds having improved binding affinity for CD154 or other trimeric proteinsZHENG ZHONGLI·Filed 2005·Application pending·0 cites
- 2548US2003235861A1Methods for designing and producing novel compounds having improved binding affinity for CD154 or other trimeric proteinsFiled 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christopher D. Benjamin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →